Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06DMQ
|
|||
| Former ID |
DIB000443
|
|||
| Drug Name |
VX-970
|
|||
| Synonyms |
VE 822
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Vertex pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H25N5O3S
|
|||
| Canonical SMILES |
CC(C)S(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C3=CC(=NO3)C4=CC=C(C=C4)CNC)N
|
|||
| InChI |
1S/C24H25N5O3S/c1-15(2)33(30,31)19-10-8-18(9-11-19)21-14-27-24(25)23(28-21)22-12-20(29-32-22)17-6-4-16(5-7-17)13-26-3/h4-12,14-15,26H,13H2,1-3H3,(H2,25,27)
|
|||
| InChIKey |
JZCWLJDSIRUGIN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1232416-25-9
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:131166
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serine/threonine-protein kinase ATR (FRP1) | Target Info | Inhibitor | [2], [3] |
| KEGG Pathway | Fanconi anemia pathway | |||
| Cell cycle | ||||
| p53 signaling pathway | ||||
| HTLV-I infection | ||||
| Panther Pathway | p53 pathway | |||
| p53 pathway feedback loops 2 | ||||
| Pathway Interaction Database | Fanconi anemia pathway | |||
| ATR signaling pathway | ||||
| Signaling events mediated by TCPTP | ||||
| Circadian rhythm pathway | ||||
| BARD1 signaling events | ||||
| p53 pathway | ||||
| Reactome | Meiotic synapsis | |||
| Activation of ATR in response to replication stress | ||||
| Regulation of HSF1-mediated heat shock response | ||||
| HDR through Single Strand Annealing (SSA) | ||||
| Processing of DNA double-strand break ends | ||||
| Presynaptic phase of homologous DNA pairing and strand exchange | ||||
| G2/M DNA damage checkpoint | ||||
| WikiPathways | DNA Damage Response | |||
| Meiotic Synapsis | ||||
| Prostate Cancer | ||||
| Integrated Breast Cancer Pathway | ||||
| Integrated Cancer pathway | ||||
| Cell Cycle | ||||
| Cell Cycle Checkpoints | ||||
| miRNA Regulation of DNA Damage Response | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79. | |||
| REF 3 | Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget. 2014 Jul 30;5(14):5674-85. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.